These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9161521)

  • 1. [How should hepatitis C be monitored? Monitoring of treated hepatitis C].
    Larrey D
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S99-110. PubMed ID: 9161521
    [No Abstract]   [Full Text] [Related]  

  • 2. [Monitoring of treated or non-treated chronic viral hepatitis C. 2: Criteria of efficacy and monitoring of treatment with interferon-alpha].
    Payen JL
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S175-89. PubMed ID: 9161529
    [No Abstract]   [Full Text] [Related]  

  • 3. Axonal neuropathy in a patient receiving interferon-alpha therapy for chronic hepatitis C.
    Tambini R; Quattrini A; Fracassetti O; Nemni R
    J Rheumatol; 1997 Aug; 24(8):1656-7. PubMed ID: 9263170
    [No Abstract]   [Full Text] [Related]  

  • 4. [Permanent hypothyroidism after interferon-alpha treatment in chronic hepatitis C].
    Fernández Soto ML; Ventosa M; Luna V; Salmerón FJ
    Med Clin (Barc); 1996 Jun; 107(2):76-7. PubMed ID: 8753901
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chronic hepatitis C: therapeutic uncertainties].
    Blondon H; Bergmann JF
    Gastroenterol Clin Biol; 1996; 20(12):1043-6. PubMed ID: 9033847
    [No Abstract]   [Full Text] [Related]  

  • 6. [Should hepatitis C be treated? Which biological tests are useful before deciding or refuting a treatment with interferon-alpha in patients with chronic hepatitis C?].
    Pawlotsky JM
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S41-50. PubMed ID: 9161513
    [No Abstract]   [Full Text] [Related]  

  • 7. [Should hepatitis C be treated?].
    Tran A
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S148-53. PubMed ID: 9161526
    [No Abstract]   [Full Text] [Related]  

  • 8. [Results of treatment of hepatitis C with interferon alone or combined with other drugs].
    Serfaty L
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S154-66. PubMed ID: 9161527
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic response to alpha-interferon in chronic alcoholics with viral hepatitis C].
    Nikitin IG; Kuznetsov SL; Liuliaeva OD; Storozhakov GI; Kisliakov VA; Uskov IuI
    Klin Med (Mosk); 1998; 76(8):33-5. PubMed ID: 9770965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypothyroidism as a complication of the treatment of hepatitis C with interferon].
    Gomollón García F; Simón Marco MA; Vela J; García López S; Fuentes Olmo J
    An Med Interna; 1996 Sep; 13(9):438-40. PubMed ID: 9132035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [How should hepatitis C be treated? Treatment of hepatitis C with interferon].
    Marcellin P
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S81-8. PubMed ID: 9161518
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of treatment with two different doses of leukocyte interferon alpha in patients with chronic hepatitis C.
    Laghi V; Toccaceli F; Rosati S; Monini A; Grimaldi M; Foglianti G; Canova N; Palazzini E
    Hepatogastroenterology; 1997; 44(16):1182-6. PubMed ID: 9261621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatitis C: screening and treatment].
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S202-11. PubMed ID: 9161531
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hepatitis C: screening and treatment].
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S213-6. PubMed ID: 9161532
    [No Abstract]   [Full Text] [Related]  

  • 15. [Should hepatitis C be treated? What are indications of treatment in chronic hepatitis C?].
    Pascal JP
    Gastroenterol Clin Biol; 1997; 21(1 Pt 2):S70-9. PubMed ID: 9161517
    [No Abstract]   [Full Text] [Related]  

  • 16. [How to follow treated and untreated chronic hepatitis B and C].
    Adler M; Golstein P; Botembe N; Bourgeois N
    Rev Med Brux; 1997 Sep; 18(4):183-6. PubMed ID: 9411639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membranoproliferative glomerulonephritis and hepatitis C: effects of interferon-alpha therapy on clinical outcome and histological pattern.
    Morosetti M; Sciarra G; Meloni C; Palmieri G; Palombo G; Taccone Gallucci M; Casciani CU
    Nephrol Dial Transplant; 1996 Mar; 11(3):532-4. PubMed ID: 8671827
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum smooth muscle antibodies with anti-actin specificity appeared during treatment with interferon alpha].
    Grimbert S; Mohib S; Johannet C; Trinchet JC; Beaugrand M
    Gastroenterol Clin Biol; 1996; 20(4):404-5. PubMed ID: 8758511
    [No Abstract]   [Full Text] [Related]  

  • 19. Vogt-Koyanagi-Harada disease associated with interferon-A and ribavirin therapy for chronic hepatitis C infection.
    Papastathopoulos K; Bouzas E; Naoum G; Vergados I; Tsiodras S
    J Infect; 2006 Feb; 52(2):e59-61. PubMed ID: 15951019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.